[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370939-105":59,"doc-detail-370939-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-efficacy-of-pembrolizumab-immunotherapy-in-the-treatment-of-endometrial-cancer-a-systematic-review","The Efficacy of Pembrolizumab Immunotherapy in the Treatment of Endometrial Cancer - A Systematic Review","","Endometrial cancer represents one of the most common gynecological cancers in women. In recent years, there has been increasing interest in immunotherapy, including the use of pembrolizumab, particularly for the treatment of cancers with deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H). A systematic review of the literature from 2020 to 2025 was conducted according to the PICO model, including six studies with 3684 patients across early-stage, advanced, metastatic, or recurrent disease.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-efficacy-of-pembrolizumab-immunotherapy-in-the-treatment-of-endometrial-cancer-a-systematic-review/370939/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-efficacy-of-pembrolizumab-immunotherapy-in-the-treatment-of-endometrial-cancer-a-systematic-review/370939.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient groups and study timeframe were included in the systematic review?","Question",{"text":112,"@type":113},"The review covered studies from 2020 to 2025 and included 3684 patients with early-stage, advanced, metastatic, or recurrent endometrial cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did pembrolizumab perform in dMMR/MSI-H versus pMMR groups?",{"text":117,"@type":113},"Pembrolizumab significantly improved progression-free survival (PFS) and overall survival (OS) in dMMR patient groups, while therapeutic benefit was limited in pMMR groups.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatments were evaluated in the included studies?",{"text":121,"@type":113},"Interventions included pembrolizumab monotherapy and pembrolizumab in combination with chemotherapy or lenvatinib.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370939,1790471168,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nThe Efficacy of Pembrolizumab Immunotherapy in the Treatment of Endometrial Cancer: A Systematic Review  \nNatalia Picheta 1, Julia Piekarz 1, Krzysztof Kułak 2, * and Rafał Tarkowski 2  \nAcademic Editor: Andras Perl  \nReceived: 23 July 2025  \nRevised: 1 September 2025  \nAccepted: 8 September 2025  \nPublished: 9 September 2025  \nCitation: Picheta, N.; Piekarz, J.; Kułak, K.; Tarkowski, R. The Efficacy of Pembrolizumab Immunotherapy in the Treatment of Endometrial Cancer: A Systematic Review. Int. J. Mol. Sci. 2025, 26, 8789. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms26188789](10.3390/ijms26188789)  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Student’s Scientific Association at the I Chair and Department of Gynaecological Oncology and Gynaecology, Medical University of Lublin, Staszica St. 16, 20-081 Lublin, Poland; [natalia.picheta2812@gmail.com](natalia.picheta2812@gmail.com) (N.P.); [piekarzjulia1@gmail.com](piekarzjulia1@gmail.com) (J.P.)  \n2 I Chair and Department of Gynaecological Oncology and Gynaecology, Medical University of Lublin, Staszica St. 16, 20-081 Lublin, Poland; [rafaltar@yahoo.com](rafaltar@yahoo.com)  \n* Correspondence: [krzysztof.kulak@gmail.com](krzysztof.kulak@gmail.com)  \nAbstract  \nEndometrial cancer represents one of the most common gynecological cancers in women. In recent years, there has been increasing interest in immunotherapy, including the use of pembrolizumab, particularly for the treatment of cancers with deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H) . A systematic review of the literature from 2020 to 2025 was conducted according to the PICO model. Six studies were included in this review, comprising four randomized clinical trials (RCTs) and two pre-specified subgroup analyses derived from previous RCTs involving a total of 3684 patients with early-stage or advanced disease or metastatic or recurrent endometrial cancer. Interventions included the use of pembrolizumabin monotherapy and in combination with chemotherapy or lenvatinib. Pembrolizumab showed a significant improvement in progression-free survival (PFS) and overall survival (OS) in the dMMR patient groups. Therapeutic benefit was limited in the proficient mismatch repair (pMMR) groups. The incidence of side effects was high but comparable to the control group. Pembrolizumab, especially in combination therapy with lenvatinib, is a promising therapeutic option for patients with dMMR/MSI-H endometrial cancer. The results suggest a potential long-term treatment effect, although the limitations of the RCT and the variability in the therapeutic regimens require further research.  \nKeywords: pembrolizumab in endometrial cancer; immunotherapy in endometrial cancer; pMMR pembrolizumab; molecular-type endometrial cancer immunotherapy; pembrolizumab vs. chemotherapy in gynecological cancer  \n1. Introduction  \nEndometrial cancer is the most common malignant tumor of the reproductive system and the fourth most common malignant tumor diagnosed in women in developed countries [1] . By 2040, endometrial cancer is projected to become the third most commonly diagnosed and the fourth leading cause of cancer-related death among women [2] . According to WHO data from 2020, 417,367 new cases were diagnosed worldwide, while 97,370 deaths were recorded. In 2019, the age-standardized incidence rate (ASIR) in Western Europe was 27.8 per 100,000 women, and in Eastern Europe, it was 27.5 . The age-standardized mortality rate (ASMR) was 3.7 and 3.2 per 100,000 women, respectively [3] . Forecasts indicate a further upward trend in morbidity and mortality in the coming decade [4] . The peak incidence is ","cbCaiuDohx76N42A","https://ap.wps.com/l/cbCaiuDohx76N42A","pdf",1035139,"English","# Abstract\n# Keywords\n# 1. Introduction\n# 2. Methods\n## 2.1. Review Design and Search Strategy","[{\"question\":\"What patient groups and study timeframe were included in the systematic review?\",\"answer\":\"The review covered studies from 2020 to 2025 and included 3684 patients with early-stage, advanced, metastatic, or recurrent endometrial cancer.\"},{\"question\":\"How did pembrolizumab perform in dMMR/MSI-H versus pMMR groups?\",\"answer\":\"Pembrolizumab significantly improved progression-free survival (PFS) and overall survival (OS) in dMMR patient groups, while therapeutic benefit was limited in pMMR groups.\"},{\"question\":\"What treatments were evaluated in the included studies?\",\"answer\":\"Interventions included pembrolizumab monotherapy and pembrolizumab in combination with chemotherapy or lenvatinib.\"}]","The Efficacy of Pembrolizumab Immunotherapy in the Treatment of Endometrial Cancer - A Systematic Review | PDF",1790190870,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/352ee87984cce2e700b3828c849aa5d5.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efe8f766e42bd51ece327645568acdfb.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89c6c9dd4cd2f3f6f01ea58eb0fbd452.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5007f08da499ad908bdf961a1e01b5f9.webp",980,1385]